prepar get wet cs deep dive ahead
clear achiev efficaci bar relev comp
agent zilucoplan gmg data includ efgartigimod
argx soliri regain base preced
look placebo-adjust delta point qmg
subject zilucoplan achiev point reduct baselin
qmg compar placebo
likelihood posit data look promis increasingli
confid po potenti zilucoplan
demonstr competit efficaci gmg especi higher dose
cohort base well-describ role complement diseas
patholog zilucoplan pnh data demonstr complement
inhibit level expect clinic relev soliri clinic
valid inhibit indic strongli posit readout
may also posit effect rarx share rais optim
indic elev expect around name
physician survey support opportun gmg recent survey
indic substanti market opportun well-pric
agent zilucoplan substanti expans beyond current market
opportun target soliri model global opportun
assum share patient
target popul small premium ivig/plex net see
posit phase data de-risk registr trial posit data
could rais po rang ad valuat
valuat reiter outperform rais tp risk
thesi includ clinic delay/failur zilucoplan gmg competit
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
ra pharma clinical-stag biopharma use proprietari peptid
chemistri platform develop novel therapeut treatment
price oct rate outperform target price analyst martin auster
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
de-risk gmg take po
unexpect safeti issu render uncompetit
what bar zilucoplan gmg trial
believ investor compar data zilucoplan argenx
efgartigimod alexion soliri studi improv
qmg versu placebo receiv favor street physician alik
absolut respond basi bar subject achiev
reduct point qmg activ arm rel placebo
increasingli confid po potenti zilucoplan
demonstr competit efficaci gmg least higher dose cohort base
well-describ role complement diseas patholog zilucoplan
pnh data demonstr complement inhibit level expect clinic
relev soliri clinic valid inhibit indic
zilucoplan sc current develop rarx gmg
drug small peptid deliv brief sec self-administ
daili subcutan small-volum inject complianc report
throughout zilucoplan studi pnh amen safeti profil poc efficaci
low incid injection-sit reaction see zilucoplan data gmg
expect key driver stock
rarx phase gmg studi enrol achr-antibodi posit patient across
dose arm zilucoplan arm placebo enrol criteria broader
soliri trial requir subject fail multipl prior therapi though
sever diseas entri criteri similar -- subject requir qmg score
moderate/sever rang manag comment us expect
baselin qmg rarx studi ballpark soliri soliri regain
baselin qmg enrol complet aug earlier expect
surpass origin target subject anticip data releas around ye
zilucoplan primari efficaci endpoint chang quantit myasthenia gravi
qmg score baselin week studi also long-term extens period
qmg standard quantit strength score system item scale
repres diseas sever qmg correl well score system util
gmg trial key secondari efficaci endpoint focu chang mg-adl
myasthenia gravi activ daili live score valid function assess
believ zilucoplan high likelihood demonstr efficaci gmg base
valid role complement caus damag neuromuscular junction
peptid believ zilucoplan abl target activ
nmj well circul
inhibit approach de-risk clinic valid soliri clinic success
zilucoplan poc achiev pnh publish data inhibit
placebo-control studi explor two dose level mg/kg mg/kg
efficaci lower dose level may allow price differenti across pnh gmg
effect dose pnh mg/kg efficaci high dose like impair
price pnh consid comp address larger gmg popul believ
zilucoplan abl achiev close full suppress complement mg/kg
believ investor see placebo-adjust delta point qmg win
trial expect subject achiev clinic
meaning reduct point qmg activ arm rel placebo
patient trial like power statist signific expect
compani test statist signific believ could potenti achiev
result come in-lin stronger expect
believ investor util mainli two trial frame zilucoplan efficaci argenx
efgartigimod pbo-control soliri regain studi pbo-control
subject enrol milder baselin qmg score compar soliri
subject drug slightli higher score patient receiv dose
efgartigimod iv pbo treatment period follow-up phase
averag decreas qmg baselin activ arm point
compar point placebo arm result consist
qmg mg-adl
subject activ arm achiev point decreas qmg score
compar subject placebo day studi
averag decreas mg-adl baselin point activ arm
compar placebo respond basi subject activ arm
achiev improv versu subject placebo day
figur efgartigimod qmg chang baselin
subject enrol baselin qmg score importantli studi enrol
relapse/refractori subject fail treatment least two immunosuppress
agent fail treatment least one immunosuppress agent requir
chronic plasma exchang ivig dose schedul induct iv eculizumab dose
mg day week mg week mainten
dose mg everi second week match placebo
primari endpoint chang baselin mg-adl score week
qmg result also report averag decreas qmg baselin
activ arm point compar point placebo arm week
separ averag chang qmg activ arm placebo seen
first dose roughli stabil around week
subject activ arm point decreas qmg score
compar subject placebo bl week
averag decreas mg-adl baselin point activ arm compar
placebo week respond basi subject activ arm
achiev improv versu subject placebo
figur soliri chang qmg baselin
what upsid stock
see posit phase data de-risk ahead registr trial could
kick-off posit data could rais po high rang
ad valuat
recent survey indic substanti market opportun zilucoplan model
global opportun assum share patient
 target popul small price premium ivig/plex net
recent run-up rarx stock indic investor start incorpor
posit outcom gmg trial continu see current price
underestim probabl success commerci opportun zilucoplan
soliri success launch relapsed/refractori gmg set
track best soliri launch across approv indic mechanist
howev clear reason expect effect sole
rarx believ lower-pr could potenti target patient
achr gmg global earlier-lin therapi rel soliri focu patient still
treatment steroids/immunosupress
ivig/plasmapheresi clinician survey see section confirm high interest
confid approach gmg price main limit factor
soliri uptak indic
survey say mg wealth opportun gmg
recent conduct physician survey particip treat patient
combin help us assess opportun gmg particip split
commun setting/hospit particip practic eu us-bas
particip experi soliri gmg anoth expect start
prescrib soliri within next month
key takeaway rarx zilucoplan
particip expect lower-cost inhibitor target broader
popul relapsed/refractori segment current target soliri
physician believ lower-cost altern could target median
gmg patient averag
particip would consid util lower-cost inhibitor averag
patient glucocorticoid immunomodulators/immunosuppress intermitt
ivig/plex averag patient chronic ivig/plex
acknowledg limit practition awar rel therapi
cost survey gener point annual cost roughli compar lower
ivig/plex maxim potenti util
figur price sensit
consid inhibitor similar efficaci safeti profil soliri percent
patient would consid prescrib drug follow price point
annual cost
annual cost
annual cost
annual cost
believ long-term commerci case zilucoplan quit promis though
acknowledg increasingli competit clinic landscap gmg
investor often inquir potenti competit dynam complement inhibit
versu fcrn antagonist major physician survey believ
complement inhibit close full suppress format fcrn
antagon block igg recycl lower lgg level like equal
efficaci manag gmg patient remaind equal split
option
charl martineau univers toronto figur percept around like efficaci base mechan action
complement role fcrn antagonist mg
complement involv mg mediat achr antibodi gmg case
mostli subclass three major pathogen mechan
antibodi bind autoantibodi achr block ach bind
internalization/degrad normal turnov receptor day bind
receptor activ complement cascad format destruct
neuromuscular junction unclear literatur talk physician
much diseas patholog driven mechan given patient
though anim model suggest complement play especi format play
major role experiment myasthenia
figur achr mg mechan diseas
zilucoplan expect promot close full suppress subsequ
prevent format approach address one three pathogen
mechan almost fulli prevent complement driven damag
theoret promis patient achiev respons base qmg
mg-adl improv soliri studi though note studi
enrol sever relapsed/refractori patient expect see similar pattern
zilucoplan wouldnt expect patient necessarili respond
complement inhibitor could potenti address major mg patient achr
though physician gener dont expect complement inhibitor effect patient
type autoantibodi musk detect patient
anoth emerg class develop gmg target neonat fc receptor fcrn
fcrn help mediat circul level igg antibodi regul antibodi
degradation/recircul igg antibodi bound fcrn recycl back circul
bound fcrn degrad fcrn antagonist compet nativ
igg antibodi bind fcrn increas rate nativ igg degrad
lower circul level igg includ autoantibodi
fcrn antagonist shown reduc circul igg antibodi level
healthi volunt base experi ivig/plex reduct greater
autoantibodi level could lead clinic efficaci though direct
correl igg lower efficaci reduct like desir
fcrn antagonist theoret potenti address achr also musk
patient reduct igg across igg subtyp report lower
circul igg autoantibodi would prevent three major pathogen mechan
mg mechan inher satur
bottom line earli declar winner
see mechanist rational approach fcrn antagon complement
inhibit wait addit efficaci data better view potenti product
profil safeti efficaci dose frequenc rout administr reassess
respect opportun approach said gmg larg indic
support multipl player view reinforc recent expert call
subset patient achiev respons clinic trial date expert expect
patient cycl therapi throughout diseas cours
revis commerci project
estim preval patient us develop
gener diseas achr-antibodi posit substanti market
opportun new agent differenti efficaci indic
rarx estim zilucoplan could util gmg patient believ
lower-cost complement inhibitor good opportun uptak patient treat
later-lin therapi ivig/plex soliri rituximab price import factor
share captur among patient immunosuppress therapi see tam
us alon depend price uptak assumpt
charl martineau univers toronto figur us tam gmg
manag
base survey result literatur review adjust commerci
assumpt gmg follow
target popul assum zilucoplan target vast major achr
gmg patient current ivig/plex later-lin therapi
patient current manag
popul patient us
immunosuppress estim
market share model launch project uptak target
popul year launch
price assum small premium ivig/plex net price
ex-u market roughli us market account larger
address popul lower penetr year
discount us price
compani mention price
